Group 1 - The core point of the article highlights that the Yin Hua Ri Li ETF (511880.SH) experienced a slight increase of 0.01% on November 11, 2025, despite significant net outflows of 1.36 billion yuan from major funds [1] - The fund's latest trading volume reached 145 million shares, while the latest trading amount fell below 15 billion yuan, marking a new low in trading volume over the past month [1]

Core Insights - The main inflows in commodity futures yesterday were in lithium carbonate, glass, aluminum, gold, and tin, with inflows of 629 million, 332 million, 171 million, 143 million, and 126 million respectively [1] - The primary outflows were in alumina, coking coal, iron ore, copper, and rebar, with outflows of 499 million, 188 million, 174 million, 91 million, and 80 million respectively [1] - Overall, commodity futures experienced a slight outflow, with black and agricultural products showing outflows, while chemical and non-ferrous metals sectors showed inflows [1] Inflow and Outflow Analysis - The chemical, non-ferrous metals, and financial sectors showed inflows, particularly in lithium carbonate, glass, gold, and aluminum, while alumina, copper, and soda ash saw outflows [1] - The agricultural and black product sectors experienced significant outflows, with a focus on coking coal, iron ore, stainless steel, live pigs, and rapeseed meal, while apples and palm oil saw contrary inflows [1] - Financial futures highlighted significant interest in the CSI 1000 index futures and 10-year treasury futures [1] Visual Data Representation - The document includes visual representations of the top ten commodity futures by capital outflow and inflow, as well as sector capital inflow amounts [3][5][6][8][10]

Core Viewpoint - The rare earth ETF (159713.SZ) experienced a decline of 1.30%, indicating a negative market sentiment towards this sector [1] Fund Performance - The main capital outflow for the fund was 832.36 million yuan, ranking it first among comparable funds [1] - The latest trading volume for the fund was 76.21 million shares, with the latest transaction amount falling below 100 million yuan, placing it in the bottom two among comparable funds [1]

Group 1: Financial Data Release - In November, the People's Bank of China is expected to release financial statistics for October, including social financing scale, M2, and new RMB loans, with anticipated figures of 16,500 million yuan for social financing and 4,700 million yuan for new loans, both lower than previous values [1] - The M2 balance is projected to grow by 8.0% year-on-year, a decrease from the previous growth rate of 8.4% [1] - A decline in these financial metrics may slightly suppress the rise of commodity futures and stock index futures, while supporting the increase in government bond futures [1] Group 2: Oil Market Reports - OPEC is set to release its monthly oil market report, which will be closely monitored for its impact on oil and related commodity futures prices [2] - The EIA will announce the weekly change in U.S. crude oil inventories, with a previous increase of 5.202 million barrels; further increases may hinder the rise in oil and related commodity futures prices [4] Group 3: U.S. Economic Indicators - The U.S. Labor Department will publish the October CPI, with expectations of a year-on-year increase of 3.0%, consistent with the previous value [3] - The core CPI is also expected to rise by 3.0% year-on-year, with a month-on-month increase of 0.2% [3] - If the U.S. government continues its shutdown, the release of the CPI data may be delayed [3] Group 4: Domestic Economic Performance - A press conference will be held to discuss the national economic performance for October, with expectations of a 5.5% year-on-year increase in industrial value added, down from 6.5% [5] - Retail sales are projected to grow by 2.8% year-on-year, slightly lower than the previous 3.0% [5] - The urban fixed asset investment for January to October is expected to decline by 0.8%, compared to a 0.5% drop for January to September [5]

Group 1 - On November 7, the main inflows in commodity futures (main contracts) were observed in aluminum, lithium carbonate, industrial silicon, iron ore, and rapeseed meal, with inflows of 1.105 billion, 0.250 billion, 0.157 billion, 0.128 billion, and 0.052 billion respectively [1] - The main outflows were in coking coal, copper, rebar, gold, and crude oil, with outflows of 0.352 billion, 0.172 billion, 0.115 billion, 0.114 billion, and 0.096 billion respectively [1] - The overall analysis indicates a slight inflow of funds into the commodity futures market on November 7, with the non-ferrous metals sector showing inflows, particularly in aluminum, lithium carbonate, industrial silicon, and nickel, while copper and gold experienced outflows [1] Group 2 - The chemical, agricultural, and black metal sectors showed outflows, with significant outflows in coking coal, rebar, crude oil, and eggs, while iron ore, rapeseed meal, and methanol saw inflows [1] - The financial sector highlights the focus on CSI 1000 index futures and 30-year treasury futures [1]

Core Insights - Company Junsheng Tai Pharmaceutical-B (02511) presented data on HTD1801 at the 58th American Society of Nephrology (ASN) annual meeting, highlighting its potential benefits for patients with mild renal impairment [1] - HTD1801 is a first-in-class anti-inflammatory metabolic modulator (AIMM) designed to address cardiorenal metabolic system diseases (CKM) through a dual mechanism of activating AMPK and inhibiting NLRP3 [1] Clinical Results - The clinical results indicate that HTD1801 significantly improves eGFR in patients with mild renal impairment compared to placebo, with a positive slope in eGFR during treatment [2] - In patients with hyperfiltration, HTD1801 was associated with a reduction in eGFR compared to placebo, suggesting its potential to promote the restoration of normal kidney function [2] - HTD1801 did not show adverse effects on blood pressure, blood sodium, or blood potassium levels [2] Study Design - The data presented is based on a pooled analysis from two Phase III randomized, double-blind, placebo-controlled clinical studies (SYMPHONY1 & 2; N=956) conducted in patients with type 2 diabetes (T2DM) [1] - The analysis included post-hoc evaluations of subgroups with mild renal impairment (baseline eGFR: 60-90 ml/min/1.73m²) and hyperfiltration (baseline eGFR ≥120 ml/min/1.73m²), focusing on eGFR changes as the primary endpoint [1]

Core Insights - The company presented data on HTD1801 at the 58th American Society of Nephrology (ASN) annual meeting, highlighting its potential kidney benefits in patients with mild renal impairment [1] - HTD1801 is a first-in-class anti-inflammatory metabolic modulator (AIMM) designed to address cardiorenal metabolic system diseases (CKM) through a dual mechanism of activating AMPK and inhibiting NLRP3 [1] - The data is based on a pooled analysis from two Phase III clinical studies (SYMPHONY 1 & 2; N=956) involving patients with type 2 diabetes (T2DM) [1] Summary by Category Clinical Results - In patients with mild renal impairment, HTD1801 significantly improved eGFR compared to placebo, with a positive slope in eGFR during treatment [2] - In patients with hyperfiltration, HTD1801 reduced eGFR compared to placebo, suggesting a potential to restore kidney function to normal levels [2] - HTD1801 did not show adverse effects on blood pressure, blood sodium, or blood potassium levels [2]

Core Viewpoint - The company announced promising clinical results for HTD1801, indicating its potential to improve kidney function in patients with mild renal impairment, showcasing significant health benefits for chronic kidney disease (CKD) patients [1][2]. Group 1: Clinical Data and Results - HTD1801 is a first-in-class anti-inflammatory metabolic modulator (AIMM) designed to address cardiorenal metabolic system diseases (CKM) by activating AMPK and inhibiting NLRP3 [1]. - The data presented is based on a pooled analysis from two Phase III randomized, double-blind, placebo-controlled studies (SYMPHONY 1 & 2; N=956) conducted in patients with type 2 diabetes (T2DM) [1]. - In patients with mild renal impairment (baseline eGFR: 60-90 ml/min/1.73m), HTD1801 significantly improved eGFR compared to placebo, with a positive slope observed during treatment [2]. - In patients with hyperfiltration (baseline eGFR ≥120 ml/min/1.73m), HTD1801 reduced eGFR compared to placebo, suggesting a potential to restore kidney function to normal levels [2]. Group 2: Safety Profile - HTD1801 did not show adverse effects on blood pressure, blood sodium, or blood potassium levels during the treatment period [2].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容而產生或因依 賴該等內容而引致的任何損失承擔任何責任。 HighTide Therapeutics, Inc. （於開曼群島註冊成立的有限公司） （股份代號：2511） 2025 ASN最新突破性專場|君聖泰醫藥展示HTD1801腎臟獲益數據 本公告由君聖泰醫藥（「本公司」，連同其附屬公司統稱為「本集團」）自願發佈，以 告知本公司股東及潛在投資者有關本集團的最新業務發展。 結果顯示，在輕度腎功能損害患者中，與安慰劑相比，HTD1801可顯著改善 eGFR，治療期間eGFR斜率呈正值；在超濾過患者中，HTD1801可相較安慰劑降 低eGFR，提示其可能促進腎功能恢復正常狀態。此外，HTD1801對血壓、血鈉 及血鉀等指標未見不良影響。 摘要標題：HTD1801在輕度腎功能損害患者中的腎臟獲益 報告編號：TH-PO1190 報告時間：2025年11月6日10:00 AM-12:00 PM 形式：壁報 1 作者：Filip Surmont, MD; Leili G ...

Group 1 - The credit bond ETF (511190.SH) experienced a slight increase of 0.03% on November 5, 2025 [1] - The main capital (transactions over 1 million yuan) saw a net outflow of 821 million yuan, ranking first among comparable funds [1] - The latest trading volume for the fund was 32.52 million units, with a total transaction amount of 3.265 billion yuan, ranking last among comparable funds [1]